Prescription ID | TCMF4658 |
Pinyin Name | Hou Pu Wen Zhong Wan |
Chinese Name | 厚朴温中丸 |
English Name | Hou Pu Wen Zhong Pills |
Function Description | 腹胀, 腹痛, 腹泻 |
Indications | Abdominal pain disorder, Diarrhea, Dyspepsia, Enteritis |
Disease ICD-11 Category |
SA58 [Abdominal pain disorder (TM1), 腹痛 (TM1)
]; ME05.1 [Diarrhoea, 腹泻 ]; MD92 [Dyspepsia, 消化不良 ]; 1A40.Z [Infectious gastroenteritis or colitis without specification of infectious agent, 未特指感染性病原体的感染性胃肠炎或结肠炎 ]; |
Human Tissues Associated with Indication | Intestine, Stomach |
Reference | CFDA |
Reference Book/link | http://samr.cfda.gov.cn/WS01/CL0001/ |
Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
---|---|---|---|---|
TCMH890 | Cortex magnoliae officinalis | 厚朴 | TCMH890 | ITSAM1591-14 |
TCMH925 | Exocarpium citri grandis | 化橘红 | TCMH925 | |
TCMH1059 | Glycine max | 姜 | TCMH1059 | ITSAJ4675-14 |
TCMH214 | Alpinia katsumadai | 草豆蔻 | TCMH214 | KY454001 |
TCMH606 | Wolfiporia cocos | 茯苓 | TCMH606 | GBPOL314-13 |
TCMH628 | Glycyrrhiza uralensis | 甘草 | TCMH628 | ITSAM892-14 |
TCMH1533 | Saussurea lappa | 木香 | TCMH1533 |
Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
---|---|---|---|---|
TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
TCMT114 | CNR2 | Cannabinoid CB2 receptor | GPCR | P34972 |
TCMT115 | CNR1 | Cannabinoid CB1 receptor | GPCR | P21554 |
TCMT127 | PARP1 | Poly [ADP-ribose] polymerase-1 | Transferase | P09874 |
TCMT128 | TNKS2 | Tankyrase-2 | Transferase | Q9H2K2 |
TCMT129 | TNKS | Tankyrase-1 | Transferase | O95271 |
TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
TCMT139 | CA6 | Carbonic anhydrase VI | Lyase | P23280 |
TCMT140 | CA5B | Carbonic anhydrase VB | Lyase | Q9Y2D0 |
TCMT141 | CA5A | Carbonic anhydrase VA | Lyase | P35218 |
TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
TCMT143 | CA3 | Carbonic anhydrase III | Lyase | P07451 |
TCMT151 | PRKCA | Protein kinase C alpha | Kinase | P17252 |
TCMT152 | PRKCB | Protein kinase C beta | Kinase | P05771 |
TCMT153 | PRKCG | Protein kinase C gamma | Kinase | P05129 |
TCMT154 | PRKCD | Protein kinase C delta | Kinase | Q05655 |
TCMT155 | PRKCE | Protein kinase C epsilon | Kinase | Q02156 |
TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
TCMT159 | TYR | Tyrosinase | Oxidoreductase | P14679 |
TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
TCMT209 | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | Oxidoreductase | P80365 |
TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
TCMT231 | GBA2 | Beta-glucosidase | Hydrolase | Q9HCG7 |
TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
TCMT249 | CDK6 | Cyclin-dependent kinase 6 | Kinase | Q00534 |
TCMT254 | CBR1 | Carbonyl reductase [NADPH] 1 | Oxidoreductase | P16152 |
TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
TCMT287 | TAS2R31 | Taste receptor type 2 member 31 | GPCR | P59538 |
TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
TCMT303 | KCNA3 | Voltage-gated potassium channel subunit Kv1.3 | Ion channel | P22001 |
TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
TCMT506 | PTK2B | Protein tyrosine kinase 2 beta | Kinase | Q14289 |
TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
TCMT599 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Transferase | P61088 |
TCMT601 | F2 | Thrombin | Unclassified | P00734 |
TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
TCMT66 | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | Oxidoreductase | P37059 |
TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
TCMT87 | CYP2C9 | Cytochrome P450 2C9 | Oxidoreductase | P11712 |
TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
Target ID | Target Name |
---|---|
TCMT1170 | Enterobacter cloacae |
TCMT1175 | Human immunodeficiency virus |
TCMT1176 | Streptococcus pneumoniae |
TCMT1178 | Actinomyces viscosus |
TCMT1179 | Escherichia coli ATCC 8739 |
TCMT1181 | Mycobacterium tuberculosis H37Ra |
TCMT1183 | Candida albicans SC5314 |
TCMT1186 | Plasmodium yoelii yoelii |
TCMT1189 | Pseudomonas fluorescens |
TCMT1201 | Staphylococcus epidermidis ATCC 12228 |
TCMT1209 | Staphylococcus haemolyticus |
TCMT1212 | Verticillium dahliae |
TCMT1214 | Enterococcus faecium |
TCMT1215 | Pseudomonas aeruginosa PAO1 |
TCMT1218 | Staphylococcus aureus |
TCMT1219 | Enterococcus |
TCMT1221 | Human herpesvirus 4 |
TCMT1222 | Plasmodium falciparum D6 |
TCMT1223 | Staphylococcus epidermidis |
TCMT1224 | Proteus mirabilis |
TCMT1226 | Klebsiella pneumoniae |
TCMT1227 | Streptococcus |
TCMT1229 | Enterococcus faecalis |
TCMT1232 | Pseudomonas aeruginosa |
TCMT1234 | Bacillus coagulans |
TCMT1235 | Clostridium sporogenes |
TCMT1236 | Mycobacterium bovis |
TCMT1237 | Mycobacterium kansasii |
TCMT1238 | Mycobacterium xenopi |
TCMT1239 | Mycobacterium marinum |
TCMT1243 | Aspergillus flavus |
TCMT1246 | Escherichia coli |
TCMT1248 | Hepatitis C virus |
TCMT1249 | Dengue virus 2 |
TCMT1251 | Candida albicans |
TCMT1253 | Penicillium chrysogenum |
TCMT1255 | Human immunodeficiency virus 1 |
TCMT1284 | Penicillium expansum |
TCMT1286 | Bacillus cereus |
TCMT1294 | Human parainfluenza virus 3 |
TCMT1346 | Helicobacter pylori |
TCMT1349 | Helicobacter pylori SS1 |
TCMT1361 | Neisseria meningitidis |
TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
TCMT1412 | Salmonella typhimurium |
TCMT1438 | Plasmodium falciparum |
TCMT1439 | Mycobacterium smegmatis |
TCMT1442 | Leishmania donovani |
TCMT1443 | Leishmania amazonensis |
TCMT1447 | Respiratory syncytial virus |
TCMT1448 | Enterobacter aerogenes |
TCMT1449 | Influenza A virus |
TCMT1450 | Plasmodium falciparum 3D7 |
TCMT1454 | Bacillus subtilis |
TCMT1455 | Mycobacterium tuberculosis H37Rv |
TCMT1457 | Leishmania major |
TCMT1458 | Filobasidiella neoformans |
TCMT1462 | Streptococcus mutans |
TCMT1463 | Mycobacterium tuberculosis |
TCMT1464 | Hepatitis B virus |
TCMT1465 | Entamoeba histolytica |
GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
---|---|---|---|
[BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 15.1111 |
[BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 14.1696 |
[BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 8.4877 |
[BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CA9, CDK6, CNR1, CNR2, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, HSD11B2, HSD17B2, PRKCE, TYR | 7.32486 |
[BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, BCL2, CA3, CA9, CDK6, CNR1, CNR2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, HSD17B2, PRKCB, PRKCD, PRKCE, TYR | 7.32486 |
[BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, BCL2, CA2, CA3, CA9, CDK6, CNR1, CNR2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP4, HSD11B2, HSD17B2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, TYR | 7.31769 |
[BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 7.14293 |
[BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, BCL2, CYP1A1, CYP1A2, CYP1B1, TYR | 7.0756 |
[BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, AOX1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CBR1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FUT7, GBA2, TYR, XDH | 6.99611 |
[BP] GO:0008152 | metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CBR1, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F2, F3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, TYR, XDH | 6.5383 |
[BP] GO:0014070 | response to organic cyclic compound | ALPL, BCL2, CA2, CA9, CNR1, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, PRKCE, PRKCG, TYR | 6.45649 |
[BP] GO:0010817 | regulation of hormone levels | ACHE, AKR1B1, CNR1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PRKCA, PRKCE | 6.35728 |
[BP] GO:0042221 | response to chemical | AKR1B1, ALPL, BCL2, CA2, CA3, CA9, CDK6, CNR1, CNR2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP4, HSD11B2, HSD17B2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, TYR | 5.64664 |
[BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CBR1, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F2, FABP4, FUT7, GBA2, HSD17B1, HSD17B2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, TYR, XDH | 5.59109 |
[BP] GO:0006629 | lipid metabolic process | ACHE, AKR1B1, AKR1B10, CBR1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.32491 |
[BP] GO:0065008 | regulation of biological quality | ACHE, AKR1B1, BCL2, CA12, CA2, CA7, CDK6, CNR1, CNR2, CYP19A1, CYP1A1, CYP1B1, ESR1, F2, F3, FABP4, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PRKCA, PRKCB, PRKCD, PRKCE, TNKS, TNKS2, XDH | 5.22699 |
[BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 5.16823 |
[BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.05901 |
[BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1, HSD17B2 | 5.04436 |
[BP] GO:0032228 | regulation of synaptic transmission, GABAergic | CA2, CA7, CNR1, CNR2, PRKCE | 4.87913 |
[BP] GO:0042493 | response to drug | AKR1B1, BCL2, CA3, CA9, CDK6, CNR1, CNR2, CYP1A1, CYP1B1, HSD11B2, PRKCD, PRKCE, PRKCG | 4.59598 |
[BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, AOX1, CBR1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 4.50587 |
[BP] GO:0018107 | peptidyl-threonine phosphorylation | BCL2, CSNK2A1, PRKCA, PRKCB, PRKCD, TNKS | 4.48542 |
[BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.4128 |
[BP] GO:0009636 | response to toxic substance | AKR1B1, ALPL, BCL2, CA3, CNR1, CNR2, CYP1A1, CYP1B1, PRKCD, PRKCE | 4.35353 |
[BP] GO:0018210 | peptidyl-threonine modification | BCL2, CSNK2A1, PRKCA, PRKCB, PRKCD, TNKS | 4.30493 |
[BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, HSD11B2, PRKCD, PRKCE | 4.26502 |
[BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 4.16016 |
[BP] GO:0018105 | peptidyl-serine phosphorylation | BCL2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, TNKS | 3.92331 |
[BP] GO:0030168 | platelet activation | F2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG | 3.69939 |
[BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1, HSD17B2 | 3.69939 |
[BP] GO:0018209 | peptidyl-serine modification | BCL2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, TNKS | 3.63961 |
[BP] GO:0010647 | positive regulation of cell communication | AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F2, F3, PRKCA, PRKCB, PRKCD, PRKCE, PTPN1, TNKS, TNKS2, XDH | 3.61246 |
[BP] GO:0023056 | positive regulation of signaling | AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F2, F3, PRKCA, PRKCB, PRKCD, PRKCE, PTPN1, TNKS, TNKS2, XDH | 3.59509 |
[BP] GO:0006694 | steroid biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.41343 |
[BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.09767 |
[BP] GO:0032844 | regulation of homeostatic process | BCL2, CA2, CA7, CDK6, CNR1, F2, PRKCE, TNKS, TNKS2 | 2.85871 |
[BP] GO:0032502 | developmental process | ACHE, AKR1B1, ALPL, BCL2, CA2, CA9, CBR1, CDC25B, CDK6, CNR1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, F2, FABP4, FUT7, GBA2, HSD11B1, HSD17B2, PRKCA, PRKCD, TNKS2, TYR | 2.79466 |
[BP] GO:0006811 | None | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, KCNA3, PRKCB, PRKCE | 2.7891 |
[BP] GO:0006703 | estrogen biosynthetic process | CYP19A1, HSD17B1, HSD17B2 | 2.78764 |
[BP] GO:0032230 | positive regulation of synaptic transmission, GABAergic | CA2, CA7, PRKCE | 2.78764 |
[BP] GO:0048584 | positive regulation of response to stimulus | AKR1B1, BCL2, CNR1, CSNK2A1, CYP1B1, ESRRA, F2, F3, FABP4, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, XDH | 2.73244 |
[BP] GO:0035408 | None | PRKCA, PRKCB | 2.69655 |
[BP] GO:0009115 | None | AOX1, XDH | 2.69655 |
[BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, HSD11B2, PRKCD, PRKCE | 2.67219 |
[BP] GO:0048513 | animal organ development | ACHE, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, ESR1, ESRRA, ESRRB, HSD11B1, HSD17B2, TYR | 2.59454 |
[BP] GO:0008631 | intrinsic apoptotic signaling pathway in response to oxidative stress | BCL2, CYP1B1, PRKCD | 2.50491 |
[BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, AKR1B10, BCL2, CYP19A1, CYP1A1, CYP1B1, GBA2, TYR | 2.49765 |
[BP] GO:0019369 | arachidonic acid metabolic process | CBR1, CYP1A1, CYP1A2, CYP1B1 | 2.48573 |
[BP] GO:0050896 | response to stimulus | ACHE, AKR1B1, ALPL, BCL2, CA2, CA3, CA6, CA9, CDK6, CNR1, CNR2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, F2, F3, FABP4, HSD11B2, HSD17B2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TYR | 2.48573 |
[BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 2.48573 |
[BP] GO:0016137 | None | AKR1B1, AKR1B10, GBA2 | 2.45287 |
[BP] GO:0010646 | regulation of cell communication | ACHE, AKR1B1, BCL2, CA2, CA7, CNR1, CNR2, CSNK2A1, CYP19A1, CYP1B1, ESR1, ESR2, F2, F3, PRKCA, PRKCB, PRKCD, PRKCE, PTPN1, TNKS, TNKS2, XDH | 2.35965 |
[BP] GO:0080134 | regulation of response to stress | CDK6, CNR1, CNR2, CYP19A1, ESR1, F2, F3, FABP4, PRKCA, PRKCD, PRKCE, PRKCG, PTPN1, XDH | 2.35965 |
[BP] GO:0046110 | None | AOX1, XDH | 2.31472 |
[BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.31472 |
[BP] GO:0023051 | regulation of signaling | ACHE, AKR1B1, BCL2, CA2, CA7, CNR1, CNR2, CSNK2A1, CYP19A1, CYP1B1, ESR1, ESR2, F2, F3, PRKCA, PRKCB, PRKCD, PRKCE, PTPN1, TNKS, TNKS2, XDH | 2.30603 |
[BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 2.28684 |
[BP] GO:0010035 | response to inorganic substance | AKR1B1, BCL2, CA2, CYP1A1, CYP1A2, CYP1B1, FABP4, PRKCD | 2.22745 |
[BP] GO:0009967 | positive regulation of signal transduction | AKR1B1, BCL2, CSNK2A1, CYP1B1, F2, F3, PRKCA, PRKCB, PRKCD, PRKCE, PTPN1, TNKS, TNKS2, XDH | 2.22745 |
[BP] GO:0032846 | positive regulation of homeostatic process | CA2, CA7, CNR1, F2, TNKS, TNKS2 | 2.20397 |
[BP] GO:0002682 | regulation of immune system process | BCL2, CA2, CDK6, CNR1, CNR2, CYP19A1, ESR1, ESRRA, F2, PRKCA, PRKCB, PRKCD, PRKCE, PTPN1 | 2.19635 |
[BP] GO:0048878 | chemical homeostasis | AKR1B1, BCL2, CA12, CA2, CA7, CNR1, ESR1, F2, FABP4, PRKCB, PRKCE | 2.19635 |
[BP] GO:1900076 | regulation of cellular response to insulin stimulus | ESRRA, PRKCB, PRKCD, PTPN1 | 2.19635 |
[BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.19529 |
[BP] GO:0032101 | regulation of response to external stimulus | CNR1, CNR2, CYP19A1, ESR1, F2, F3, FABP4, PRKCA, PRKCD, PRKCG | 2.15667 |
[BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.14662 |
[BP] GO:0061041 | regulation of wound healing | F2, F3, PRKCA, PRKCD, PRKCE | 2.11469 |
[BP] GO:0048522 | positive regulation of cellular process | ACHE, AKR1B1, BCL2, CA2, CA7, CDC25B, CDK6, CNR1, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F2, F3, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, XDH | 2.11024 |
[BP] GO:0070213 | None | TNKS, TNKS2 | 2.09596 |
[BP] GO:0006145 | None | AOX1, XDH | 2.09596 |
[BP] GO:0038171 | None | CNR1, CNR2 | 2.09596 |
[BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.09596 |
[CC] GO:0044444 | cytoplasmic part | ACHE, AKR1B1, AKR1B10, AOX1, BCL2, CA1, CA2, CA3, CA4, CA5A, CA5B, CA7, CBR1, CDC25B, CDK6, CNR1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, F2, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, TYR, XDH | 2.83734 |
[CC] GO:0048471 | perinuclear region of cytoplasm | ACHE, AKR1B1, CA4, PRKCA, PRKCD, PRKCE, PRKCG, TNKS2, TYR | 2.07409 |
[CC] GO:0044432 | endoplasmic reticulum part | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, F2, GBA2, HSD11B1, HSD11B2, HSD17B2, PTPN1 | 1.30671 |
[CC] GO:0016020 | membrane | ACHE, ALPL, BCL2, CA12, CA14, CA2, CA4, CA9, CNR1, CNR2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, F2, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B2, KCNA3, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, TYR | 1.28353 |
[CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2 | 1.21742 |
[MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 21.3951 |
[MF] GO:0046914 | transition metal ion binding | AOX1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, PRKCA, PRKCB, PRKCG, PTPN1, TNKS, TYR, XDH | 15.1111 |
[MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 14.1696 |
[MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 12.6679 |
[MF] GO:0003824 | catalytic activity | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CBR1, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, F2, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, TYR, XDH | 9.99464 |
[MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, PRKCA, PRKCB, PRKCG, PTPN1, TNKS | 9.6623 |
[MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 8.4877 |
[MF] GO:0043169 | cation binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, TYR, XDH | 7.09912 |
[MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, CBR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, XDH | 7.00559 |
[MF] GO:0046872 | metal ion binding | ALPL, AOX1, CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F2, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, TYR, XDH | 6.66133 |
[MF] GO:0043167 | ion binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F2, F3, FABP4, HSD17B1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PTPN1, TNKS, TNKS2, TYR, XDH | 6.37226 |
[MF] GO:0004697 | None | PRKCA, PRKCB, PRKCD, PRKCE, PRKCG | 6.37226 |
[MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, AOX1, CBR1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 5.5156 |
[MF] GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | AKR1B1, AKR1B10, CBR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.77726 |
[MF] GO:0004698 | None | PRKCA, PRKCB, PRKCG | 4.4128 |
[MF] GO:0005496 | steroid binding | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1 | 4.28486 |
[MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.75924 |
[MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.58757 |
[MF] GO:0033764 | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.52706 |
[MF] GO:0016229 | steroid dehydrogenase activity | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.41343 |
[MF] GO:0009931 | None | PRKCA, PRKCB, PRKCG | 2.96786 |
[MF] GO:0010857 | None | PRKCA, PRKCB, PRKCG | 2.85871 |
[MF] GO:0005506 | iron ion binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH | 2.85008 |
[MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.77551 |
[MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 2.75476 |
[MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 2.72795 |
[MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.69655 |
[MF] GO:0003845 | None | HSD11B1, HSD11B2 | 2.69655 |
[MF] GO:0035403 | None | PRKCA, PRKCB | 2.69655 |
[MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | ESR1, ESR2, ESRRA, ESRRB | 2.62606 |
[MF] GO:0004879 | nuclear receptor activity | ESR1, ESR2, ESRRA, ESRRB | 2.62606 |
[MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.58062 |
[MF] GO:0003707 | steroid hormone receptor activity | ESR1, ESR2, ESRRA, ESRRB | 2.35965 |
[MF] GO:0004949 | None | CNR1, CNR2 | 2.31472 |
[MF] GO:0004699 | None | PRKCD, PRKCE | 2.31472 |
[MF] GO:0048037 | cofactor binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B2, HSD17B1, XDH | 2.12627 |
[MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.09596 |
KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
---|---|---|
Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA5B, CA3, CA5A, CA2, CA4, CA7, CA6, CA9, CA14 | 22.8294 |
Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD11B2, HSD17B1, HSD17B2, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 9.9442 |
AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | PRKCB, PRKCE, PRKCD, BCL2, PRKCA, F3 | 5.158 |
Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 | 5.158 |
Metabolic pathways_Homo sapiens_hsa01100 | CBR1, AKR1B1, TYR, GBA2, CYP19A1, HSD11B1, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALPL, XDH | 5.1565 |
MicroRNAs in cancer_Homo sapiens_hsa05206 | PRKCG, CDK6, PRKCB, PRKCE, BCL2, CYP1B1, PRKCA, CDC25B | 4.768 |
Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CBR1, CYP1A2, CYP1A1, CYP1B1 | 4.6659 |
Tight junction_Homo sapiens_hsa04530 | PRKCG, CSNK2A1, PRKCB, PRKCE, PRKCD, PRKCA | 4.6405 |
Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | PRKCG, PRKCB, PRKCE, PRKCD, PRKCA | 4.3003 |
Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | PRKCG, PRKCB, PRKCE, PRKCD, PRKCA | 4.3776 |
Cholinergic synapse_Homo sapiens_hsa04725 | PRKCG, ACHE, PRKCB, BCL2, PRKCA | 4.0975 |
Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CBR1, CYP1A2, CYP1A1, CYP1B1 | 4.5233 |
Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.4219 |
Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | PRKCG, HSD11B2, PRKCB, PRKCA | 4.4255 |
Non-small cell lung cancer_Homo sapiens_hsa05223 | PRKCG, CDK6, PRKCB, PRKCA | 4.0119 |
Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | PRKCG, PRKCB, PRKCA, ESR1 | 4.242 |
Vascular smooth muscle contraction_Homo sapiens_hsa04270 | PRKCG, PRKCB, PRKCE, PRKCD, PRKCA | 4.0119 |
Glioma_Homo sapiens_hsa05214 | PRKCG, CDK6, PRKCB, PRKCA | 3.8099 |
Sphingolipid signaling pathway_Homo sapiens_hsa04071 | PRKCG, PRKCB, PRKCE, BCL2, PRKCA | 4.0119 |
Hepatitis B_Homo sapiens_hsa05161 | PRKCG, CDK6, PRKCB, BCL2, PRKCA | 3.6469 |
Gastric acid secretion_Homo sapiens_hsa04971 | PRKCG, PRKCB, CA2, PRKCA | 3.6304 |
Aldosterone synthesis and secretion_Homo sapiens_hsa04925 | PRKCG, PRKCB, PRKCE, PRKCA | 3.4962 |
Melanogenesis_Homo sapiens_hsa04916 | PRKCG, PRKCB, PRKCA, TYR | 3.212 |
Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | PRKCG, PRKCB, CNR1, PRKCA | 3.2116 |
HIF-1 signaling pathway_Homo sapiens_hsa04066 | PRKCG, PRKCB, BCL2, PRKCA | 3.1944 |
Pancreatic secretion_Homo sapiens_hsa04972 | PRKCG, PRKCB, CA2, PRKCA | 3.2637 |
Insulin resistance_Homo sapiens_hsa04931 | PTPN1, PRKCB, PRKCE, PRKCD | 3.1148 |
Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | PRKCG, PRKCB, PRKCA, ESR1 | 2.997 |
Wnt signaling pathway_Homo sapiens_hsa04310 | PRKCG, CSNK2A1, PRKCB, PRKCA | 2.721 |
Long-term depression_Homo sapiens_hsa04730 | PRKCG, PRKCB, PRKCA | 2.721 |
mTOR signaling pathway_Homo sapiens_hsa04150 | PRKCG, PRKCB, PRKCA | 2.721 |
VEGF signaling pathway_Homo sapiens_hsa04370 | PRKCG, PRKCB, PRKCA | 2.7129 |
Amphetamine addiction_Homo sapiens_hsa05031 | PRKCG, PRKCB, PRKCA | 2.63 |
African trypanosomiasis_Homo sapiens_hsa05143 | PRKCG, PRKCB, PRKCA | 3.2817 |
Proteoglycans in cancer_Homo sapiens_hsa05205 | PRKCG, PRKCB, PRKCA, ESR1 | 2.3274 |
ErbB signaling pathway_Homo sapiens_hsa04012 | PRKCG, PRKCB, PRKCA | 2.3415 |
Insulin secretion_Homo sapiens_hsa04911 | PRKCG, PRKCB, PRKCA | 2.3527 |
Long-term potentiation_Homo sapiens_hsa04720 | PRKCG, PRKCB, PRKCA | 2.6373 |
Focal adhesion_Homo sapiens_hsa04510 | PRKCG, PRKCB, BCL2, PRKCA | 2.3274 |
Retinol metabolism_Homo sapiens_hsa00830 | CYP1A2, CYP1A1, AOX1 | 2.6445 |
GABAergic synapse_Homo sapiens_hsa04727 | PRKCG, PRKCB, PRKCA | 2.3415 |
Rap1 signaling pathway_Homo sapiens_hsa04015 | PRKCG, PRKCB, CNR1, PRKCA | 2.2959 |
GnRH signaling pathway_Homo sapiens_hsa04912 | PRKCB, PRKCD, PRKCA | 2.3392 |
Thyroid hormone synthesis_Homo sapiens_hsa04918 | PRKCG, PRKCB, PRKCA | 2.5682 |
Salivary secretion_Homo sapiens_hsa04970 | PRKCG, PRKCB, PRKCA | 2.3392 |
Gap junction_Homo sapiens_hsa04540 | PRKCG, PRKCB, PRKCA | 2.3415 |
Morphine addiction_Homo sapiens_hsa05032 | PRKCG, PRKCB, PRKCA | 2.3392 |
Circadian entrainment_Homo sapiens_hsa04713 | PRKCG, PRKCB, PRKCA | 2.3218 |
Pathways in cancer_Homo sapiens_hsa05200 | PRKCG, CDK6, PRKCB, BCL2, PRKCA | 2.1409 |
NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, PRKCB, BCL2 | 2.3274 |
Estrogen signaling pathway_Homo sapiens_hsa04915 | PRKCD, ESR1, ESR2 | 2.2959 |
Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | PRKCG, PRKCB, PRKCA | 2.2959 |
Choline metabolism in cancer_Homo sapiens_hsa05231 | PRKCG, PRKCB, PRKCA | 2.2873 |
Amoebiasis_Homo sapiens_hsa05146 | PRKCG, PRKCB, PRKCA | 2.2917 |
MAPK signaling pathway_Homo sapiens_hsa04010 | PRKCG, PRKCB, PRKCA, CDC25B | 2.0867 |
Glutamatergic synapse_Homo sapiens_hsa04724 | PRKCG, PRKCB, PRKCA | 2.1686 |
Serotonergic synapse_Homo sapiens_hsa04726 | PRKCG, PRKCB, PRKCA | 2.1754 |
Oxytocin signaling pathway_Homo sapiens_hsa04921 | PRKCG, PRKCB, PRKCA | 1.8359 |
Leukocyte transendothelial migration_Homo sapiens_hsa04670 | PRKCG, PRKCB, PRKCA | 2.1409 |
Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | PRKCG, PRKCB, PRKCA | 2.0115 |
Dopaminergic synapse_Homo sapiens_hsa04728 | PRKCG, PRKCB, PRKCA | 2.0599 |
Calcium signaling pathway_Homo sapiens_hsa04020 | PRKCG, PRKCB, PRKCA | 1.6944 |
Ras signaling pathway_Homo sapiens_hsa04014 | PRKCG, PRKCB, PRKCA | 1.4643 |
Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | CNR2, CNR1, F2 | 1.2517 |
PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | CDK6, BCL2, PRKCA | 1.0661 |
Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | BCL2, PRKCA | 1.0717 |
Jak-STAT signaling pathway_Homo sapiens_hsa04630 | BCL2, AOX1 | 1.0318 |
Measles_Homo sapiens_hsa05162 | CDK6, CSNK2A1 | 1.1318 |
Neurotrophin signaling pathway_Homo sapiens_hsa04722 | PRKCD, BCL2 | 1.2139 |
Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, BCL2 | 0.8867 |
Cell cycle_Homo sapiens_hsa04110 | CDK6, CDC25B | 1.1935 |
Influenza A_Homo sapiens_hsa05164 | PRKCB, PRKCA | 0.9792 |
Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | F2 | 0.374 |
Viral carcinogenesis_Homo sapiens_hsa05203 | CDK6 | 0.3848 |
Chemokine signaling pathway_Homo sapiens_hsa04062 | PRKCB, PRKCD | 0.9389 |
Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.4369 |
Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.4262 |
Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.416 |
Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.4257 |
cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | PRKCE | 0.4375 |
Apoptosis_Homo sapiens_hsa04210 | BCL2 | 0.4897 |
Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.4897 |
Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.4881 |
Phospholipase D signaling pathway_Homo sapiens_hsa04072 | PRKCA | 0.4866 |
Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.5807 |
Toxoplasmosis_Homo sapiens_hsa05145 | BCL2 | 0.5453 |
Small cell lung cancer_Homo sapiens_hsa05222 | CDK6, BCL2 | 1.4643 |
Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | CDC25B | 0.6119 |
Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.6202 |
Prostate cancer_Homo sapiens_hsa05215 | BCL2 | 0.6415 |
Complement and coagulation cascades_Homo sapiens_hsa04610 | F2, F3 | 1.5223 |
Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.5701 |
Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.6415 |
Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP1A2, AOX1 | 1.6098 |
Peroxisome_Homo sapiens_hsa04146 | XDH | 0.6611 |
Chronic myeloid leukemia_Homo sapiens_hsa05220 | CDK6 | 0.7077 |
B cell receptor signaling pathway_Homo sapiens_hsa04662 | PRKCB | 0.7077 |
Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | PRKCA | 0.7106 |
Melanoma_Homo sapiens_hsa05218 | CDK6 | 0.7077 |
Leishmaniasis_Homo sapiens_hsa05140 | PRKCB | 0.7077 |
Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.7077 |
Pancreatic cancer_Homo sapiens_hsa05212 | CDK6 | 0.716 |
p53 signaling pathway_Homo sapiens_hsa04115 | CDK6 | 0.7106 |
PPAR signaling pathway_Homo sapiens_hsa03320 | FABP4 | 0.7106 |
Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.7275 |
Colorectal cancer_Homo sapiens_hsa05210 | BCL2 | 0.7368 |
Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4 | 0.7696 |
Arachidonic acid metabolism_Homo sapiens_hsa00590 | CBR1 | 0.7368 |
Pathogenic Escherichia coli infection_Homo sapiens_hsa05130 | PRKCA | 0.7726 |
Vibrio cholerae infection_Homo sapiens_hsa05110 | PRKCA | 0.7989 |
Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.7989 |
Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | PRKCB | 0.8277 |
Type II diabetes mellitus_Homo sapiens_hsa04930 | PRKCE, PRKCD | 1.8877 |
Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.8147 |
Sphingolipid metabolism_Homo sapiens_hsa00600 | GBA2 | 0.819 |
Drug metabolism - other enzymes_Homo sapiens_hsa00983 | XDH | 0.8233 |
Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 2.2111 |
Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.9682 |
Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.9863 |
Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.3392 |
Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1, TYR | 2.1228 |
Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 2.1708 |
Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.9863 |
Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 2.1056 |
Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 1.0176 |
Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 1.0067 |
Other glycan degradation_Homo sapiens_hsa00511 | GBA2 | 1.1473 |
Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 1.2381 |
Caffeine metabolism_Homo sapiens_hsa00232 | CYP1A2, XDH | 3.4454 |
Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.5701 |